X0508 4 2023-07-25 0 0001764974 Turnstone Biologics Corp. TSBX 0001619298 Versant Ventures V, LLC ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001589097 Versant Venture Capital V, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001589098 Versant Ophthalmic Affiliates I, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001589095 Versant Affiliates Fund V, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001619297 Versant Ventures V GP-GP (Canada), Inc. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001716490 Versant Ventures V (Canada), L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001612235 Versant Venture Capital V (Canada), LP ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001839789 Versant Vantage II GP-GP, LLC ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001839790 Versant Vantage II GP, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0001832235 Versant Vantage II, L.P. ONE SANSOME STREET, SUITE 1650 SAN FRANCISCO CA 94104 0 0 1 0 0 Common Stock 2023-07-25 4 C 0 2528864 A 2528864 I By Versant Venture Capital V, L.P. Common Stock 2023-07-25 4 C 0 192458 A 192458 I By Versant Venture Capital V (Canada) LP Common Stock 2023-07-25 4 C 0 84313 A 84313 I By Versant Ophthalmic Affiliates Fund I, L.P. Common Stock 2023-07-25 4 C 0 76067 A 76067 I By Versant Affiliates Fund V, L.P. Common Stock 2023-07-25 4 C 0 274990 A 274990 I By Versant Vantage II, L.P. Common Stock 2023-07-25 4 P 0 197458 12.00 A 2726322 I By Versant Venture Capital V, L.P. Common Stock 2023-07-25 4 P 0 15028 12.00 A 207486 I By Versant Venture Capital V (Canada) LP Common Stock 2023-07-25 4 P 0 6575 12.00 A 90888 I By Versant Ophthalmic Affiliates Fund I, L.P. Common Stock 2023-07-25 4 P 0 5939 12.00 A 82006 I By Versant Affiliates Fund V, L.P. Series A Preferred Stock 2023-07-25 4 C 0 7897999 0.00 D Common Stock 988832 0 I By Versant Venture Capital V, L.P. Series A Preferred Stock 2023-07-25 4 C 0 601077 0.00 D Common Stock 75255 0 I By Versant Venture Capital V (Canada) LP Series A Preferred Stock 2023-07-25 4 C 0 263349 0.00 D Common Stock 32971 0 I By Versant Ophthalmic Affiliates Fund I, L.P. Series A Preferred Stock 2023-07-25 4 C 0 237575 0.00 D Common Stock 29744 0 I By Versant Affiliates Fund V, L.P. Series B-1 Preferred Stock 2023-07-25 4 C 0 3530789 0.00 D Common Stock 442055 0 I By Versant Venture Capital V, L.P. Series B-1 Preferred Stock 2023-07-25 4 C 0 268711 0.00 D Common Stock 33642 0 I By Versant Venture Capital V (Canada) LP Series B-1 Preferred Stock 2023-07-25 4 C 0 117730 0.00 D Common Stock 14739 0 I By Versant Ophthalmic Affiliates Fund I, L.P. Series B-1 Preferred Stock 2023-07-25 4 C 0 106208 0.00 D Common Stock 13297 0 I By Versant Affiliates Fund V, L.P. Series B-2 Preferred Stock 2023-07-25 4 C 0 7650043 0.00 D Common Stock 957787 0 I By Versant Venture Capital V, L.P. Series B-2 Preferred Stock 2023-07-25 4 C 0 582206 0.00 D Common Stock 72892 0 I By Versant Venture Capital V (Canada) LP Series B-2 Preferred Stock 2023-07-25 4 C 0 255081 0.00 D Common Stock 31936 0 I By Versant Ophthalmic Affiliates Fund I, L.P. Series B-2 Preferred Stock 2023-07-25 4 C 0 230117 0.00 D Common Stock 28810 0 I By Versant Affiliates Fund V, L.P. Series C Preferred Stock 2023-07-25 4 C 0 1119729 0.00 D Common Stock 140190 0 I By Versant Venture Capital V, L.P. Series C Preferred Stock 2023-07-25 4 C 0 85217 0.00 D Common Stock 10669 0 I By Versant Venture Capital V (Canada) LP Series C Preferred Stock 2023-07-25 4 C 0 37283 0.00 D Common Stock 4667 0 I By Versant Ophthalmic Affiliates Fund I, L.P. Series C Preferred Stock 2023-07-25 4 C 0 33682 0.00 D Common Stock 4216 0 I By Versant Affiliates Fund V, L.P. Series D Preferred Stock 2023-07-25 4 C 0 2196402 0.00 D Common Stock 274990 0 I By Versant Vantage II, L.P. Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Venture Capital V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Ophthalmic Affiliates Fund I, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Affiliates Fund V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Ventures V GP-GP (Canada), Inc., By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Ventures V (Canada), L.P., By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Venture Capital V (Canada), LP, By Versant Ventures V (Canada), L.P., its general partner, By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Vantage II GP-GP, LLC, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Vantage II GP, L.P., By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27 Versant Vantage II, L.P., By Versant Vantage II GP, L.P., its general partner, By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer 2023-07-27